Evidence map›Paper›PMID 40138074›Full record

ArticleEJNMMI radiopharmacy and chemistry2025

Synthesis and preclinical evaluation of gastrin releasing peptide receptor antagonist [

Panagiotis Kanellopoulos, Fanny Lundmark, Ayman Abouzayed, Lorenzo Jacopo Ilic Balestri, Esther Olaniran Håkansson, Karim Obeid, Luke R Odell, Vladimir Tolmachev, Ulrika Rosenström, Jonas Eriksson and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Panagiotis Kanellopoulos *Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Fanny Lundmark *Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Ayman AbouzayedDepartment of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Lorenzo Jacopo Ilic BalestriDepartment of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Esther Olaniran HåkanssonDepartment of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Karim ObeidDepartment of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Luke R OdellDepartment of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Vladimir TolmachevDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Ulrika RosenströmDepartment of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Jonas ErikssonDepartment of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Anna OrlovaDepartment of Medicinal Chemistry, Uppsala University, Uppsala, Sweden. anna.orlova@ilk.uu.se.ORCID http://orcid.org/0000-0001-6120-2683

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe gastrin-releasing peptide receptor (GRPR) is overexpressed in the majority of primary prostate cancer lesions, with persistent expression in lymph nodes and bone metastases, making it a legitimate molecular target for diagnostic imaging and staging. This study presents the synthesis and preclinical evaluation of [

resultsThe labelling of TCO-PEG

conclusionsThese findings demonstrate the effectiveness of the IEDDA click reaction for fluorine-18 labelling of GRPR-targeting PET tracers. Future studies should focus on increasing the hydrophilicity of the imaging probe to improve the targeting properties and biodistribution profile of the radioligand.

Indexed as

BombesinFluorine-18GRPRIEDDA click chemistryPETProstate cancerTCOTetrazine

Identifiers

PMID40138074
PMCPMC11947346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.